FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for obtaining aflibercept from a host cell cultured in a chemically defined medium (CDM). The proposed method includes the cultivation of the host cell in CDM under suitable conditions, and the cumulative concentration of nickel in CDM is not more than 0.4 mcmol, the cumulative concentration of iron is not more than 55.0 mcmol, the cumulative concentration of copper is not more than 0.8 mcmol, the cumulative concentration of zinc is not more than 56.0 mcmol, the cumulative concentration of cysteine is not more than 10.0 mcmol, and the cumulative concentration of antioxidant is from 0.001 mmol to 10.0 mmol.
EFFECT: invention allows to get aflibercept with increased productivity.
16 cl, 59 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2795973C1 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PREPARATION | 2020 |
|
RU2788949C1 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2785994C1 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2016 |
|
RU2769470C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
